Top

Published in:

01-07-2012 | Original Contribution

Mesenchymal stem cells neither fully acquire the electrophysiological properties of mature cardiomyocytes nor promote ventricular arrhythmias in infarcted rats

Authors: Feng Wei, Ting-Zhong Wang, Jing Zhang, Zu-Yi Yuan, Hong-Yan Tian, Ya-Juan Ni, Xiao-Zhen Zhuo, Ke Han, Yu Liu, Qun Lu, Hong-Yuan Bai, Ai-Qun Ma

Published in: Basic Research in Cardiology | Issue 4/2012

Abstract

Electrophysiological properties of implanted mesenchymal stem cells (MSCs) in infarcted hearts remain unclear, and their proarrhythmic effect is still controversial. The intent of this study was to investigate electrophysiological properties and proarrhythmic effects of MSCs in infarcted hearts. Rats were randomly divided into a myocardial infarction (MI) group, a MI-DMEM group (received DMEM medium injection) and MI-MSCs group (received MSCs injection). Survival analysis showed that the majority of engrafted MSCs died at day 9 after transplantation. Engrafted MSCs expressed cardiac markers (MYH, cTnI, Cx43), cardiac ion channel genes (Kv1.4, Kv4.2 and Kir2.1) and potassium currents (I _to, I _K1 and I _KDR), but did not express Nav1.5, Cav1.2, Na⁺ current and Ca²⁺ current during their survival. When induced by Ca²⁺, implanted MSCs exhibited no contraction ability after being isolated from the heart. Following 8-week electrocardiography monitoring, the cumulative occurrence of ventricular arrhythmias (VAs) was not different among the three groups. However, the prolonged QRS duration in infarcted rats without VAs was significantly decreased in the MI-MSCs group compared with the other two groups. The inducibility of VAs in the MI-MSCs group was much lower than that in the MI and MI-DMEM groups (41.20 vs. 86.67 % and 92.86 %; P < 0.0125). The ventricular effective refractory period in MI-MSCs group was prolonged in comparison with that in the MI and MI-DMEM groups (56.0 ± 8.8 vs. 47.7 ± 8.8 ms and 45.7 ± 6.2 ms; P < 0.01). These results demonstrate that MSCs do not acquire the electrophysiological properties of mature cardiomyocytes during the survival period in the infarcted hearts. However, they can alleviate the electrical vulnerability and do not promote ventricular arrhythmias.

Available only for authorised users

Asp L, Beraki S, Kristensson K, Ogren SO, Karlsson H (2009) Neonatal infection with neurotropic influenza A virus affects working memory and expression of type III Nrg1 in adult mice. Brain Behav Immun 23:733–741. doi:10.1016/j.bbi.2009.04.004 PubMedCrossRef

Assmus B, Honold J, Schachinger V, Britten MB, Fischer-Rasokat U, Lehmann R, Teupe C, Pistorius K, Martin H, Abolmaali ND, Tonn T, Dimmeler S, Zeiher AM (2006) Transcoronary transplantation of progenitor cells after myocardial infarction. New Engl J Med 355:1222–1232. doi:10.1056/nejmoa051779 PubMedCrossRef

Beeres S, Zeppenfeld K, Bax JJ, Dibbets-Schneider P, Stokkel MPM, Fibbe WE, van der Wall EE, Atsma DE, Schalij MJ (2007) Electrophysiological and arrhythmogenic effects of intramyocardial bone marrow cell injection in patients with chronic ischemic heart disease. Heart Rhythm 4:257–265. doi:10.1016/j.hrthm.2006.10.033 PubMedCrossRef

Bolli R, Chugh AR, D’Amario D, Loughran JH, Stoddard MF, Ikram S, Beache GM, Wagner SG, Leri A, Hosoda T, Sanada F, Elmore JB, Goichberg P, Cappetta D, Solankhi NK, Fahsah I, Rokosh DG, Slaughter MS, Kajstura J, Anversa P (2011) Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 378:1847–1857. doi:10.1016/s0140-6736(11)61590-0 PubMedCrossRef

Briguori C, Reimers B, Sarais C, Napodano M, Pascotto P, Azzarello G, Bregni M, Porcellini A, Vinante O, Zanco P, Peschle C, Condorelli G, Colombo A (2006) Direct intramyocardial percutaneous delivery of autologous bone marrow in patients with refractory myocardial angina. Am Heart J 151:674–680. doi:10.1016/j.ahj.2005.04.033 PubMedCrossRef

Chang MG, Tung L, Sekar RB, Chang CY, Cysyk J, Dong PH, Marban E, Abraham R (2006) Proarrhythmic potential of mesenchymal stem cell transplantation revealed in an in vitro coculture model. Circulation 113:1832–1841. doi:10.1161/circulationaha.105.593038 PubMedCrossRef

Chen SL, Fang W, Ye F, Liu YH, Qian J, Shan S, Zhang J, Zhao RCH, Liao LM, Lin S, Sun JP (2004) Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 94:92–95. doi:10.1016/j.amjcard.2004.03.034 PubMedCrossRef

Cho J, Zhai P, Maejima Y, Sadoshima J (2011) Myocardial injection with GSK-3 beta-overexpressing bone marrow-derived mesenchymal stem cells attenuates cardiac dysfunction after myocardial infarction. Circ Res 108:478–489. doi:10.1161/circresaha.110.229658 PubMedCrossRef

Du Y, Huang X, Wang T, Han K, Zhang J, Xi Y, Wu G, Ma A (2007) Downregulation of neuronal sodium channel subunits Nav1.1 and Nav1.6 in the sinoatrial node from volume-overloaded heart failure rat. Pflug Arch Eur J Phy 454:451–459. doi:10.1007/s00424-007-0216-4 CrossRef

10.

Enoki C, Otani H, Sato D, Okada T, Hattori R, Imamura H (2010) Enhanced mesenchymal cell engraftment by IGF-1 improves left ventricular function in rats undergoing myocardial infarction. Int J Cardiol 138:9–18. doi:10.1016/j.ijcard.2009.04.012 PubMedCrossRef

11.

Fuchs S, Kornowski R, Weisz G, Satler LF, Smits PC, Okubagzi P, Baffour R, Aggarwal A, Weissman NJ, Cerqueira M, Waksman R, Serrruys P, Battler A, Moses JW, Leon MB, Epstein SE (2006) Safety and feasibility of transendocardial autologous bone marrow cell transplantation in patients with advanced heart disease. Am J Cardiol 97:823–829. doi:10.1016/j.amjcard.2005.09.132 PubMedCrossRef

12.

Fukushima S, Varela-Carver A, Coppen SR, Yamahara K, Felkin LE, Lee J, Barton PJR, Terracciano CMN, Yacoub MH, Suzuki K (2007) Direct intramyocardial but not intracoronary injection of bone marrow cells induces ventricular arrhythmias in a rat chronic ischemic heart failure model. Circulation 115:2254–2261. doi:10.1161/circulationaha.106.662577 PubMedCrossRef

13.

Gao E, Lei YH, Shang XY, Huang ZM, Zuo L, Boucher M, Fan QA, Chuprun JK, Ma XL, Koch WJ (2010) A novel and efficient model of coronary artery ligation and myocardial infarction in the mouse. Circ Res 107:1445–1453. doi:10.1161/circresaha.110.223925 PubMedCrossRef

14.

Grauss RW, van Tuyn J, Steendijk P, Winter EM, Pijnappels DA, Hogers B, Groot A, van der Geest R, van der Laarse A, de Vries AAF, Schalij MJ, Atsmaa DE (2008) Forced myocardin expression enhances the therapeutic effect of human mesenchymal stem cells after transplantation in ischemic mouse hearts. Stem Cells 26:1083–1093. doi:10.1634/stemcells.2007-0523 PubMedCrossRef

15.

Hagege AA, Marolleau JP, Vilquin JT, Alheritiere A, Peyrard S, Duboc D, Abergel E, Messas E, Mousseaux E, Schwartz K, Desnos M, Menasche P (2006) Skeletal myoblast transplantation in ischemic heart failure—long-term follow-up of the first phase I cohort of patients. Circulation 114:I108–I113. doi:10.1161/circulationaha.105.000521 PubMedCrossRef

16.

Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS, Hermiller JB, Reisman MA, Schaer GL, Sherman W (2009) A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 54:2277–2286. doi:10.1016/j.jacc.2009.06.055 PubMedCrossRef

17.

Heusch G (2011) SCIPIO brings new momentum to cardiac cell therapy. Lancet 378:1827–1828. doi:10.1016/s0140-6736(11)61648-6 PubMedCrossRef

18.

Huang J, Zhang ZP, Guo JA, Ni AG, Deb A, Zhang LN, Mirotsou M, Pratt RE, Dzau VJ (2010) Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium. Circ Res 106:1753–1762. doi:10.1161/circresaha.109.196030 PubMedCrossRef

19.

Janssens S, Dubois C, Bogaert J, Theunissen K, Deroose C, Desmet W, Kolantzi M, Herbots L, Sinnaeve P, Dens J, Maertens J, Rademakers F, Dymarkowski S, Gheysens O, Van Cleemput J, Bormans G, Nuyts J, Belmans A, Mortelmans L, Boogaerts M, Van de Werf F (2006) Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 367:113–121. doi:10.1016/S0140-6736(05)67861-0 PubMedCrossRef

20.

Jiang W, Ma A, Wang T, Han K, Liu Y, Zhang Y, Dong A, Du Y, Huang X, Wang J, Lei X, Zheng X (2006) Homing and differentiation of mesenchymal stem cells delivered intravenously to ischemic myocardium in vivo: a time-series study. Pflug Arch Eur J Phy 453:43–52. doi:10.1007/s00424-006-0117-y CrossRef

21.

Jin JY, Jeong SI, Shin YM, Lim KS, Shin HS, Lee YM, Koh HC, Kim KS (2009) Transplantation of mesenchymal stem cells within a poly(lactide-co-epsilon-caprolactone) scaffold improves cardiac function in a rat myocardial infarction model. Eur J Heart Fail 11:147–153. doi:10.1093/eurjhf/hfn017 PubMedCrossRef

22.

Katritsis DG, Sotiropoulou P, Giazitzoglou E, Karvouni E, Papamichail M (2007) Electrophysiological effects of intracoronary transplantation of autologous mesenchymal and endothelial progenitor cells. Europace 9:167–171. doi:10.1093/europace/eul184 PubMedCrossRef

23.

Li GR, Deng XL, Sun HY, Chung SSM, Tse HF, Lau CP (2006) Ion channels in mesenchymal stem cells from rat bone marrow. Stem Cells 24:1519–1528. doi:10.1634/stemcells.2005-0307 PubMedCrossRef

24.

Li Q, Guo Y, Ou Q, Chen N, Wu WJ, Yuan F, O’Brien E, Wang T, Luo L, Hunt GN, Zhu X, Bolli R (2011) Intracoronary administration of cardiac stem cells in mice: a new, improved technique for cell therapy in murine models. Basic Res Cardiol 106:849–864. doi:10.1007/s00395-011-0180-1 PubMedCrossRef

25.

Li WZ, Ma N, Ong LL, Nesselmann C, Klopsch C, Ladilov Y, Furlani D, Piechaczek C, Moebius JM, Lutzow K, Lendlein A, Stamm C, Li RK, Steinhoff G (2007) Bc1-2 engineered MSCs inhibited apoptosis and improved heart function. Stem Cells 25:2118–2127. doi:10.1634/stemcells.2006-0771 PubMedCrossRef

26.

Lorenzen JM, Martino F, Thum T (2012) Epigenetic modifications in cardiovascular disease. Basic Res Cardiol 107:245. doi:10.1007/s00395-012-0245-9 PubMedCrossRef

27.

Lunde K, Solheim S, Aakhus S, Arnesen H, Abdelnoor M, Egeland T, Endresen K, Ilebekk A, Mangschau A, Fjeld JG, Smith HJ, Taraldsrud E, Grogaard HK, Bjornerheim R, Brekke M, Muller C, Hopp E, Ragnarsson A, Brinchmann JE, Forfang K (2006) Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. New Engl J Med 355:1199–1209. doi:10.1056/nejmoa055706 PubMedCrossRef

28.

Lunde K, Solheim S, Forfang K, Arnesen H, Brinch L, Jornerheim R, Ragnarsson A, Egeland T, Endresen K, Ilebekk A, Mangschau A, Aakhus S (2008) Anterior myocardial infarction with acute percutaneous coronary intervention and intracoronary injection of autologous mononuclear bone marrow cells—safety, clinical outcome, and serial changes in left ventricular function during 12-months’ follow-up. J Am Coll Cardiol 51:674–676. doi:10.1016/j.jacc.2007.10.032 PubMedCrossRef

29.

Ly HQ, Nattel S (2009) Stem cells are not proarrhythmic: letting the genie out of the bottle. Circulation 119:1824–1831. doi:10.1161/circulationaha.108.812701 PubMedCrossRef

30.

Macia E, Boyden PA (2009) Stem cell therapy is proarrhythmic. Circulation 119:1814–1823. doi:10.1161/circulationaha.108.779900 PubMedCrossRef

31.

Madonna R, Rokosh G, De Caterina R, Bolli R (2010) Hepatocyte growth factor/Met gene transfer in cardiac stem cells—potential for cardiac repair. Basic Res Cardiol 105:443–452. doi:10.1007/s00395-010-0102-7 PubMedCrossRef

32.

Mangi AA, Noiseux N, Kong DL, He HM, Rezvani M, Ingwall JS, Dzau VJ (2003) Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 9:1195–1201. doi:10.1038/nm912 PubMedCrossRef

33.

Menasche P, Hagege AA, Vilquin JT, Desnos M, Abergel E, Pouzet B, Bel A, Sarateanu S, Scorsin M, Schwartz K, Bruneval P, Benbunan M, Marolleau JP, Duboc D (2003) Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol 41:1078–1083. doi:10.1016/S0735-1097(03)00092-5 PubMedCrossRef

34.

Mills W, Mal N, Kiedrowski M, Unger R, Forudi F, Popovic Z, Penn M, Laurita K (2007) Stem cell therapy enhances electrical viability in myocardial infarction. J Mol Cell Cardiol 42:304–314. doi:10.1016/j.yjmcc.2006.09.011 PubMedCrossRef

35.

Numasawa Y, Kimura T, Miyoshi S, Nishiyama N, Hida N, Tsuji H, Tsuruta H, Segawa K, Ogawa S, Umezawa A (2011) Treatment of human mesenchymal stem cells with angiotensin receptor blocker improved efficiency of cardiomyogenic transdifferentiation and improved cardiac function via angiogenesis. Stem Cells 29:1405–1414. doi:10.1002/stem.691 PubMed

36.

Oerlemans MI, Goumans MJ, van Middelaar B, Clevers H, Doevendans PA, Sluijter JP (2010) Active Wnt signaling in response to cardiac injury. Basic Res Cardiol 105:631–641. doi:10.1007/s00395-010-0100-9 PubMedCrossRef

37.

Ohtani K, Dimmeler S (2011) Control of cardiovascular differentiation by microRNAs. Basic Res Cardiol 106:5–11. doi:10.1007/s00395-010-0139-7 PubMedCrossRef

38.

Orlandi A, Chavakis E, Seeger F, Tjwa M, Zeiher AM, Dimmeler S (2010) Long-term diabetes impairs repopulation of hematopoietic progenitor cells and dysregulates the cytokine expression in the bone marrow microenvironment in mice. Basic Res Cardiol 105:703–712. doi:10.1007/s00395-010-0109-0 PubMedCrossRef

39.

Pak HN, Qayyum M, Kim DT, Hamabe A, Miyauchi Y, Lill MC, Frantzen M, Takizawa K, Chen LS, Fishbein MC, Sharifi BG, Chen PS, Makkar R (2003) Mesenchymal stem cell injection induces cardiac nerve sprouting and increased tenascin expression in a swine model of myocardial infarction. J Cardiovasc Electr 14:841–848. doi:10.1046/j.1540-8167.2003.03124.x CrossRef

40.

Pasha Z, Wang Y, Sheikh R, Zhang D, Zhao T, Ashraf M (2008) Preconditioning enhances cell survival and differentiation of stem cells during transplantation in infarcted myocardium. Cardiovasc Res 77:134–142. doi:10.1093/cvr/cvm025 PubMedCrossRef

41.

Rosova I, Dao M, Capoccia B, Link D, Nolta JA (2008) Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Stem Cells 26:2173–2182. doi:10.1634/stemcells.2007-1104 PubMedCrossRef

42.

Russell KC, Phinney DG, Lacey MR, Barrilleaux BL, Meyertholen KE, O’Connor KC (2010) In vitro high-capacity assay to quantify the clonal heterogeneity in trilineage potential of mesenchymal stem cells reveals a complex hierarchy of lineage commitment. Stem Cells 28:788–798. doi:10.1002/stem.312 PubMedCrossRef

43.

Sanganalmath SK, Abdel-Latif A, Bolli R, Xuan YT, Dawn B (2011) Hematopoietic cytokines for cardiac repair: mobilization of bone marrow cells and beyond. Basic Res Cardiol 106:709–733. doi:10.1007/s00395-011-0183-y PubMedCrossRef

44.

Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holschermann H, Yu JT, Corti R, Mathey DG, Hamm CW, Suselbeck T, Assmus B, Tonn T, Dimmeler S, Zeiher AM, Investigators R-A (2006) Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. New Engl J Med 355:1210–1221. doi:10.1056/nejmoa060186 PubMedCrossRef

45.

Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holschermann H, Yu JT, Corti R, Mathey DG, Hamm CW, Suselbeck T, Werner N, Haase J, Neuzner J, Germing A, Mark B, Assmus B, Tonn T, Dimmeler S, Zeiher AM, Investigators RA (2006) Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J 27:2775–2783. doi:10.1093/eurheartj/ehl388 PubMedCrossRef

46.

Shinmura D, Togashi I, Miyoshi S, Nishiyama N, Hida N, Tsuji H, Tsuruta H, Segawa K, Tsukada Y, Ogawa S, Umezawa A (2011) Pretreatment of human mesenchymal stem cells with pioglitazone improved efficiency of cardiomyogenic transdifferentiation and cardiac function. Stem Cells 29:357–366. doi:10.1002/stem.574 PubMedCrossRef

47.

Song H, Hwang HJ, Chang W, Song BW, Cha MJ, Kim IK, Lim S, Choi EJ, Ham O, Lee CY (2011) Cardiomyocytes from phorbol myristate acetate-activated mesenchymal stem cells restore electromechanical function in infarcted rat hearts. Proc Natl Acad Sci USA 108:296–301. doi:10.1073/pnas.1015873107 PubMedCrossRef

48.

Stamm C, Kleine HD, Westphal B, Petzsch M, Kittner C, Nienaber CA, Freund M, Steinhoff G (2004) CABG and bone marrow stem cell transplantation after myocardial infarction. Thorac Cardiov Surg 52:152–158. doi:10.1055/s-2004-817981 CrossRef

49.

Tang YL, Tang Y, Zhang YC, Qian KP, Shen LP, Phillips I (2005) Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. J Am Coll Cardiol 46:1339–1350. doi:10.1016/j.jacc.2005.05.079 PubMedCrossRef

50.

Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD (2002) Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 105:93–98. doi:10.1161/hc0102.101442 PubMedCrossRef

51.

Tsuji H, Miyoshi S, Ikegami Y, Hida N, Asada H, Togashi I, Suzuki J, Satake M, Nakamizo H, Tanaka M, Mori T, Segawa K, Nishiyama N, Inoue J, Makino H, Miyado K, Ogawa S, Yoshimura Y, Umezawa A (2010) Xenografted human amniotic membrane-derived mesenchymal stem cells are immunologically tolerated and transdifferentiated into cardiomyocytes. Circ Res 106:1613–1623. doi:10.1161/circresaha.109.205260 PubMedCrossRef

52.

Walker MJA, Curtis MJ, Hearse DJ, Campbell RWF, Janse MJ, Yellon DM, Cobbe SM, Coker SJ, Harness JB, Harron DWG, Higgins AJ, Julian DG, Lab MJ, Manning AS, Northover BJ, Parratt JR, Riemersma RA, Riva E, Russell DC, Sheridan DJ, Winslow E, Woodward B (1988) The lambeth conventions-guidelines for the study of arrhythmias in ischemia, infarction, and reperfusion. Cardiovasc Res 22:447–455. doi:10.1093/cvr/22.7.447 PubMedCrossRef

53.

Wang D, Zhang F, Shen W, Chen M, Yang B, Zhang Y, Cao K (2010) Mesenchymal stem cell injection ameliorates the inducibility of ventricular arrhythmias after myocardial infarction in rats. Int J Cardiol 152:314–320. doi:10.1016/j.ijcard.2010.07.025 PubMedCrossRef

54.

Wang SP, Wang JA, Luo RH, Cui WY, Wang H (2008) Potassium channel currents in rat mesenchymal stem cells and their possible roles in cell proliferation. Clin Exp Pharmacol Physiol 35:1077–1084. doi:10.1111/j.1440-1681.2008.04964 PubMedCrossRef

55.

Wang TZ, Xu ZY, Jiang WH, Ma AQ (2006) Cell-to-cell contact induces mesenchymal stem cell to differentiate into cardiomyocyte and smooth muscle cell. Int J Cardiol 109:74–81. doi:10.1016/j.ijcard.2005.05.072 PubMedCrossRef

56.

Wei F, Wang TZ, Liu JJ, Du Y, Ma AQ (2011) The subpopulation of mesenchymal stem cells that differentiate toward cardiomyocytes is cardiac progenitor cells. Exp Cell Res 317:2661–2670. doi:10.1016/j.yexcr.2011.08.011 PubMedCrossRef

57.

White HD, Chew DP (2008) Acute myocardial infarction. Lancet 372:570–584. doi:10.1016/S0140-6736(08)61237-4 PubMedCrossRef

58.

Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lippolt P, Breidenbach C, Fichtner S, Korte T, Hornig B, Messinger D, Arseniev L, Hertenstein B, Ganser A, Drexler H (2004) Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 364:141–148. doi:10.1016/S0140-6736(04)16626-9 PubMedCrossRef

59.

Wu J, Li J, Zhang N, Zhang C (2011) Stem cell-based therapies in ischemic heart diseases: a focus on aspects of microcirculation and inflammation. Basic Res Cardiol 106:317–324. doi:10.1007/s00395-011-0168-x PubMedCrossRef

Title: Mesenchymal stem cells neither fully acquire the electrophysiological properties of mature cardiomyocytes nor promote ventricular arrhythmias in infarcted rats
Authors: Feng Wei
Ting-Zhong Wang
Jing Zhang
Zu-Yi Yuan
Hong-Yan Tian
Ya-Juan Ni
Xiao-Zhen Zhuo
Ke Han
Yu Liu
Qun Lu
Hong-Yuan Bai
Ai-Qun Ma
Publication date: 01-07-2012
Publisher: Springer-Verlag
Published in: Basic Research in Cardiology / Issue 4/2012
Print ISSN: 0300-8428
Electronic ISSN: 1435-1803
DOI: https://doi.org/10.1007/s00395-012-0274-4

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Mesenchymal stem cells neither fully acquire the electrophysiological properties of mature cardiomyocytes nor promote ventricular arrhythmias in infarcted rats

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2012

Remote ischemic preconditioning confers late protection against myocardial ischemia–reperfusion injury in mice by upregulating interleukin-10

Postconditioning with glucagon like peptide-2 reduces ischemia/reperfusion injury in isolated rat hearts: role of survival kinases and mitochondrial KATP channels

Cardiac vulnerability to ischemia/reperfusion injury drastically increases in late pregnancy

Cardioprotection by clopidogrel in acute ST-elevated myocardial infarction patients: a retrospective analysis

Inhibition of RIP1-dependent necrosis prevents adverse cardiac remodeling after myocardial ischemia–reperfusion in vivo

Emerging beneficial roles of sirtuins in heart failure

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page